Friday 19
- Brain and leptomeningeal metastasis: Standard of diagnosis and treatment
- Clinical implementation of PARP inhibitors
- Emerging opportunities in cancer immunotherapy
- Exosomes and other EVs, why are they important?
- Standards and advances in rectal cancer
- State of the art for systemic treatments in kidney and bladder cancers
Saturday 20
- Neo-adjuvant therapy management of early breast cancer
- What is new in the management of recurrent ovarian cancer
- Adjuvant treatment in colon cancer: Standards and next steps
- Novel therapies for small cell lung cancer
- Precision medicine with chemotherapy
- Multimodality approaches to hepatobiliary cancers
Sunday 21
- Opportunities in clinic trial design in the era of genomics and immuno-oncology
- The critical need of a multidisciplinary approach for the treatment of prostate cancer
- Optimal antineoplastic therapy and supportive care of elderly cancer patients
- Revisiting systemic therapy in HNSCC in the era of immunotherapy
- Sarcomas as a key foundation for molecular-targeted basket trials
- Unresolved questions in melanoma
Monday 22
- Multiple myeloma
- Epigenetics
- The force awakens: Immunotherapy in thoracic malignancies
- Undifferentiated sarcomas: From MFH to UPS with more distance still to travel
- State of the art management of GEP- NET
- Clinical implementation of PI3K inhibitors
- Affordability and sustainability of new cancer drugs